Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.
Friday June 3rd: LBA7502
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
